TherapeuticsMD, Inc. short interest in 2026
In 2026, TherapeuticsMD, Inc.'s disclosed short interest ran from 0.76% of shares outstanding on 15 Jan 2026 to 0.23% on 15 Sep 2026, a change of -0.53 percentage points. The year's high was 0.76% on 15 Jan 2026 and its low 0.23% on 31 Aug 2026, averaging 0.40% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.27 days on 29 May 2026. Full history: TherapeuticsMD, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 0.76% (15 Jan 2026)
- End of year
- 0.23% (15 Sep 2026)
- Change
- -0.53 pp
- High
- 0.76% (15 Jan 2026)
- Low
- 0.23% (31 Aug 2026)
- Average
- 0.40%
- Highest days to cover
- 3.27 (29 May 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 0.76% | 1.00 | |
| 30 Jan 2026 | 0.41% | 1.00 | |
| 13 Feb 2026 | 0.41% | 1.00 | |
| 27 Feb 2026 | 0.39% | 2.23 | |
| 13 Mar 2026 | 0.41% | 1.99 | |
| 31 Mar 2026 | 0.42% | 2.25 | 10-K filed, results (8-K) |
| 15 Apr 2026 | 0.45% | 2.13 | |
| 30 Apr 2026 | 0.49% | 2.72 | |
| 15 May 2026 | 0.46% | 2.33 | 10-Q filed, results (8-K) |
| 29 May 2026 | 0.44% | 3.27 | |
| 15 Jun 2026 | 0.40% | 1.00 | |
| 30 Jun 2026 | 0.49% | 1.56 | |
| 15 Jul 2026 | 0.37% | 1.58 | |
| 31 Jul 2026 | 0.25% | 1.36 | |
| 14 Aug 2026 | 0.24% | 1.84 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 0.23% | 1.00 | |
| 15 Sep 2026 | 0.23% | 1.27 |
See also: TherapeuticsMD, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.